Shares of UCB SA (OTCMKTS:UCBJY – Get Free Report) hit a new 52-week high on Tuesday . The company traded as high as $98.65 and last traded at $98.59, with a volume of 9802 shares changing hands. The stock had previously closed at $97.31.
UCB Stock Up 1.3 %
The company has a current ratio of 1.19, a quick ratio of 0.78 and a debt-to-equity ratio of 0.33. The business has a fifty day moving average price of $92.17 and a 200 day moving average price of $80.80.
About UCB
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.
Read More
- Five stocks we like better than UCB
- Where Do I Find 52-Week Highs and Lows?
- Palantir Cracks $50, Is There Still Time to Get on Board?
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Insider Buying Signals Upside for These 3 Stocks
- The Most Important Warren Buffett Stock for Investors: His Own
- These 2 Big Players Are Set to Compete With Elon Musk’s Starlink
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
